Last reviewed 2026-04-20 · How we verify

Abrocitinib Suspension F1 (abrocitinib-suspension-f1)

Abrocitinib Suspension F1 is a marketed drug by Pfizer Inc. It targets the JAK1 protein, a key player in inflammation. Abrocitinib Suspension F1 is used to treat moderate to severe atopic dermatitis in adults and children 12 years of age and older. This drug offers clinical differentiation through its high efficacy and rapid onset of action. Commercially, Abrocitinib Suspension F1 has achieved significant revenue of $21.2B. There are no pipeline developments mentioned for this drug.

At a glance

Approved indications

• Moderate to severe atopic dermatitis in adults
• Moderate to severe atopic dermatitis in children 12 years of age and older

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• Live vaccines
• Bacillus Calmette-Guérin (BCG) vaccine
• Other vaccines
• Live attenuated influenza vaccine
• Toxoids
• Inactivated vaccines
• Interferon-alpha
• Interferon-beta
• Interferon-gamma
• TNF-alpha inhibitors
• TNF-beta inhibitors

Key clinical trials

• A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Abrocitinib Suspension F1 CI brief — competitive landscape report
• Abrocitinib Suspension F1 updates RSS · CI watch RSS
• Pfizer portfolio CI